Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Novo Nordisk agonist shows strong trial results as MASH cases rise among US adults For the first time, a GLP-1 therapy has been cleared to treat metabolic dysfunction-associated steatohepatitis (MASH), after the US Food and Drug Administration (FDA) granted accelerated approval to Novo Nordisks weight-loss drug Wegovy
High-Fiber Foods Dietary fibre plays a significant role in increasing GLP-1 levels, as it slows down digestion, which promotes satiety and stimulates GLP-1 secretion
Importantly, GLP-1 appears to attenuate reward-driven food consumption by modulating dopaminergic signaling in the mesolimbic system, potentially reducing preference for high-fat, energy-dense foods [36]
Link to study Behm, F
US$ 24.34
US$ 26.47
:max_bytes(150000):strip_icc()/VWH-GettyImages-2059065209-7ab09bdd0be8409493ace4364fccf792.jpg)
US$ 22.40
/assets/images/provider/photos/2775922.jpeg)
US$ 21.88
US$ 29.57
